Paris, France – October 13, 2014 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today the second payment of €1.144 k from Bpifrance as part as the funding granted to support the NICE consortium.
Taking into account the development of the Strategic Industrial Innovation (ISI) program and based on the completion of the first milestone “Etape clé 1”, Bpifrance has proceed to transfer €1.144 k to Nanobiotix. In January 2014, Nanobiotix has received an initial payment of €461 k from Bpifrance.
Nanobiotix pursued the non-clinical evaluation phase of NBTXR3 with a view to initiating a clinical trial of NBTXR3 in patients suffering from liver cancer. In this population of patients, the aim of using the product is to increase and prolong patients’ survival. This non-clinical evaluation phase should allow Nanobiotix to initiate the clinical development in these cancer diseases in 2015.
In July 2013, Bpifrance granted NICE consortium with a funding of almost €9 million, including €2.8 million directly attributable to Nanobiotix through the Strategic Industrial Innovation (ISI) program which is dedicated to accelerate the clinical and industrial development of the Company’s lead product NBTXR3 in liver cancers.
About NICE consortium
The NICE (Nano Innovation for CancEr) consortium consists of five public and private partners with in depth expertise in the field of nanomedicine. Its mission is to build the first French platform to accelerate the development and industrialization of nanomedicine.
In addition to Nanobiotix, the consortium includes Onxeo (ex BioAlliance Pharma) which is developing Livatag®; CEA-Leti, the developer of Lipidots® platform nanoparticles; DBI, a company specialized in the production of nanomedicine pharmaceutical products and the Institut Galien Paris Sud (University Paris Sud/CNRS), which has an academic-excellence team specialized in nanoparticle research.
The consortium has been accredited by the Medicen Paris Region, a competitive cluster for innovative therapies in Ile-de-France (www.medicen.org).
About NANOBIOTIX: www.nanobiotix.com
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers (Soft Tissue Sarcoma, Breast Cancer, Liver Cancer, H&N cancer, Glioblastoma, Prostate…) via multiple routes of administration.
Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.
Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).
Issued for and on behalf of Nanobiotix by Instinctif Partners.
To contact the Nanobiotix team at Instinctif Partners, email email@example.com.
Melanie Toyne-SewellManaging Partner